Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366553 | 0.97 | DRD2 (0.61) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL17364137 | 0.92 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL29354894 | 0.92 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL28644153 | 0.89 | DRD2 (0.73) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL17368147 | 0.87 | DRD2 (0.67) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25690904 | 0.83 | DRD2 (0.62) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| Pridopidine SCHEMBL29664816 | 0.79 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL166748 | 0.79 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25614171 | 0.79 | DRD2 (0.56) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| Pridopidine SCHEMBL2370301 | 0.78 | DRD2 (0.97) | DRD2SIGMAR1DRD3HTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | DRD2 15/4885SIGMAR1 826/4885DRD3 55/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.